Central Pharmaceutical JSC No2 (HSTC:DP2) Cash-to-Debt: 0.00 (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HSTC:DP2 Central Pharmaceutical JSC No2 HSTC:DP2
23 GF Score
Price ₫4,900.00
View Full Analysis

What is Central Pharmaceutical JSC No2 Cash-to-Debt?

Central Pharmaceutical JSC No2 HSTC:DP2 23 Cash-to-Debt is 0.00 as of . 20. GuruFocus rates HSTC:DP2 with a GF Score™ of 23/100.

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Central Pharmaceutical JSC No2's cash to debt ratio for the quarter that ended in . 20 was 0.00.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Central Pharmaceutical JSC No2 couldn't pay off its debt using the cash in hand for the quarter that ended in . 20.

The historical rank and industry rank for Central Pharmaceutical JSC No2's Cash-to-Debt or its related term are showing as below:

HSTC:DP2's Cash-to-Debt is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 0.8
* Ranked among companies with meaningful Cash-to-Debt only.

Central Pharmaceutical JSC No2  (HSTC:DP2) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Central Pharmaceutical JSC No2 Cash-to-Debt Related Terms

Central Pharmaceutical JSC No2 Cash-to-Debt Historical Data

* Premium members only.

The historical data trend for Central Pharmaceutical JSC No2's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Central Pharmaceutical JSC No2 Cash-to-Debt Chart

Central Pharmaceutical JSC No2 Annual Data
Trend
Cash-to-Debt

Central Pharmaceutical JSC No2 Semi-Annual Data
Cash-to-Debt

HSTC:DP2 vs : Cash-to-Debt Comparison

For the Pharmaceutical Retailers subindustry, Central Pharmaceutical JSC No2's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Central Pharmaceutical JSC No2 Cash-to-Debt vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Central Pharmaceutical JSC No2's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Central Pharmaceutical JSC No2's Cash-to-Debt falls into.


HSTC:DP2
23GF Score
Central Pharmaceutical JSC No2 HSTC:DP2
Cash-to-Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Central Pharmaceutical JSC No2 Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Central Pharmaceutical JSC No2's Cash to Debt Ratio for the fiscal year that ended in . 20 is calculated as:

Do not have enough data to calculate Cash to Debt ratio.

Central Pharmaceutical JSC No2's Cash to Debt Ratio for the quarter that ended in . 20 is calculated as:

Do not have enough data to calculate Cash to Debt ratio.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash-to-Debt →
What does a Cash-to-Debt of 0.00 mean?
Central Pharmaceutical JSC No2 (HSTC:DP2) has a Cash-to-Debt of 0.00 as of . 20.
Is Central Pharmaceutical JSC No2's Cash-to-Debt too high?
Central Pharmaceutical JSC No2's current Cash-to-Debt is 0.00. Overall, Central Pharmaceutical JSC No2 has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Central Pharmaceutical JSC No2's Cash-to-Debt compare to ?
Central Pharmaceutical JSC No2's Cash-to-Debt of 0.00 can be compared against companies in the Healthcare Providers & Services industry. The industry median Cash-to-Debt is 0.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Healthcare Providers & Services company?
The median Cash-to-Debt among Healthcare Providers & Services companies is 0.80, based on 671 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median Cash-to-Debt is 0.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Central Pharmaceutical JSC No2's current Cash-to-Debt is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Central Pharmaceutical JSC No2 stock overvalued right now?
Central Pharmaceutical JSC No2 (HSTC:DP2) has a current Cash-to-Debt of 0.00. The current Cash-to-Debt is 0.00. Central Pharmaceutical JSC No2's overall GF Score™ is 23/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Central Pharmaceutical JSC No2 (HSTC:DP2), the current Cash-to-Debt is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Central Pharmaceutical JSC No2 Business Description

Comparable Companies
Address No. 9 Tran Thanh Tong, Bach Dang Ward, Hai Ba Trung District, Hanoi, VNM
Central Pharmaceutical JSC No2 is engaged in the Trading of medicinal materials, pharmaceutical materials, chemicals, essential oils, modern medicines, traditional medicine drugs, cosmetics, and nutritious foods. Some of its products include Gentamycin injection solution 80; Genatreson Skin Cream; Ferimax Hard Capsules and others.
23GF Score

Get the complete analysis for HSTC:DP2

Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₫4,900.00
Price